2J girdle muscular dystrophy, bibliographic review and report of a pediatric case in Ecuador
DOI:
https://doi.org/10.47464/MetroCiencia/vol28/3/2020/8-13Keywords:
Limb-Girdle Muscular Dystrophy, skeletal muscle, quality of lifeAbstract
Limb girdle muscular dystrophy (LGMD) includes several disorders with heterogeneous etiologies. They are inherited in an autosomal recessive or autosomal dominant pattern and constitute the fourth most common genetic cause of muscle weakness, reporting a prevalence of 1 in 20,000. The clinical manifestations are nonspecific, can begin from early childhood to adulthood depending on the subtype of the disease and the protein affected. The initial diagnosis is made by genetic testing before obtaining a muscle biopsy. To date there are no treatments that modify the evolution of the disease. The purpose of therapy is to preserve functional independence and treat associated complications, maintaining quality of life as much as possible. The following is the case of a pediatric patient, resident in Quito, Ecuador with no prior family or pathological history, with progressive fine motor disorder due to motor disorder in the hands, flexed fingers, hypotrophy of tenar and hypothenar eminences, and atrophy of interosseous hands, studies are performed in relation to distal peripheral neuropathy with bilateral and symmetrical sensitivity involvement, finding electromyographic changes as the only variant: chronic, sensitive and motor polyneuropathy with axonal predominance (demyelinating to a lesser degree), of marked degree presumably of hereditary etiology. The final diagnosis was determined by a genetic study with a mutation of the TTN gene in relation to: Girdle Muscular dystrophy, type 2J (DISTAL PREDOMINANT SCAPULAR GIRDLE).
Downloads
References
Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2014; 83:1453.
Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954; 77: 169–231.
Wicklund MP. The muscular dystrophies. Continuum (Minneap Minn) 2013; 19:1535.
Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol 2014; 33:1.
Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on LimbGirdle Dystrophies. Neuromuscul Disord 1995;5:71–74. 3.
Bushby KM, Beckmann JS. The limb-girdle muscular dystrophies: proposal for a new nomenclature. Neuromuscul Disord 1995;5:337–343.
Pegoraro E, Hoffman EP. Limb-Girdle Muscular Dystrophy Overview. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews®. Seattle: University of Washington; 1993-2015 [updated 2012 Aug 30; cited 2015 Dec 29]. Available from: http://goo.gl/36pH26.
Wicklund MP, Kissel JT. Las distrofias musculares de la cintura escapular. Neurol Clin 2014; 32: 729.
Pogue R, Anderson LV, Pyle A, Sewry C, Pollitt C, Johnson MA, Davison K, Moss JA, Mercuri E, Muntoni F, Bushby KM. Estrategia para el análisis de mutaciones en las distrofias musculares de la cintura y la extremidad autosómica recesiva. Trastorno neuromuscular. 2001; 11 : 80–7.
Albahaca T Darras, MD. Limb-girdle muscular dystrophy Uptodate 2018.
Nigro V, Piluso G. Next generation sequencing (NGS) strategies for the genetic testing of myopathies. Acta Myol 2012;31:196-200.
Roberts, A. M., Ware, J. S., Herman, D. S., Schafer, S., Baksi, J., Bick, A. G. Cook, S. A. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Science Translational Medicine, 2015, 7(270), 270ra6–270ra6. doi:10.1126/scitranslmed.3010134
Penisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. J Neurol Neurosurg Psychiatry 2010;81:1200-2.
Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002;30:201-4.
Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005;64:636-42.
Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol 1993;50:604-8.
Carmignac V, Salih MA, Quijano-Roy S, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007;61:340-51.
Guglieri, M., Straub, V., Bushby, K., & Lochmüller, H. Limb–girdle muscular dystrophies. Current Opinion in Neurology, 2008, 21(5), 576–584. doi:10.1097/wco.0b013e32830efdc2.
Norwood F, de Visser M, Eymard B, et al. EFNS Guideline Task Force. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies [Review]. Eur J Neurol 2007; 14:1305–1312.
Mitsuhashi, S., & Kang, P. B. Update on the Genetics of Limb Girdle Muscular Dystrophy. Seminars in Pediatric Neurology, 2012, 19(4), 211–218. doi:10.1016/j.spen.2012.09.008.
Bushby K, Straub V. Nonmolecular treatment for muscular dystrophies [Review]. Curr Opin Neurol 2005; 18:511–518.
Danie`le N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies [Review]. Int J Biochem Cell Biol 2007; 39:1608–1624.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Liliana Reyes, Pablo Villamar, Nicolás Espinosa

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


